August 2, 2023
PHC Corporation (headquarters: Minato-ku, Tokyo, President, Representative Director: Nobuaki Nakamura, hereafter PHC), a wholly-owned subsidiary of PHC Holdings Corporation (headquarters: Minato-ku, Tokyo), and Cyfuse Biomedical K.K. (headquarters: Minato-ku, Tokyo, Representative Director: Shizuka Akieda, hereafter Cyfuse) announce that they entered a strategic alliance to jointly develop products to advance regenerative and cellular medicine.
PHC is a global healthcare company that develops, manufactures, sells, and services solutions in the business domains of Diabetes Management and Diagnostics & Life Sciences. PHC’s In Vitro Diagnostics Division has partnered with a wide range of companies in the last 30 years to develop and manufacture high-performance medical devices, including blood glucose monitoring (BGM) systems. Cyfuse offers proprietary technology in bio-3D printing, which seeks to use cells to create three-dimensional forms that can then create tissue for application in regenerative medicine. The company is advancing its clinical development of innovative regenerative medicine products and seeks to commercialize new treatment options for nerves, bone and cartilage, and blood vessels.
Under this new partnership, PHC and Cyfuse will combine their respective technologies and expertise to pursue joint development of regenerative and cellular medicine treatment options, by accelerating the development of Cyfuse’s regenerative medicine-related products.
The two companies also plan to respond to market growth in regenerative and cellular medicine by expanding the value chain in this area, through research and development of new products.
PHC and Cyfuse Strategic Alliance
Hiroyuki Tokunaga, Board Member of PHC and Director of its IVD Division, said, “We look forward to collaborating with Cyfuse to advance practical applications for regenerative and cellular medicine. Together we will seek to offer new value to healthcare providers and accelerate growth in the area of regenerative and cellular medicine. We will also seek to expand options for treatment by automating processes related to cell culture that currently require manual procedures.”
Norihiko Tokunaga, Director and Head of System Development of Cyfuse, said, “We are excited about this strong new partnership with PHC Group, a global healthcare company, and the potential for commercialization of new healthcare solutions. We will combine our expertise to establish a manufacturing system for the area of regenerative and cellular medicine, explore new healthcare markets, and contribute to the further development and practical use of our regenerative medicine products.”
About PHC Corporation
Established in 1969, PHC Corporation is a Japanese subsidiary of PHC Holdings Corporation (TSE 6523), or PHC Group, a global healthcare company that develops, manufactures, sells and services solutions across diabetes management, healthcare solutions, and diagnostics & life sciences. PHC Corporation provides medical devices, as well as develops research and medical support equipment for new modalities in life sciences. PHC Group subsidiaries also include Ascensia Diabetes Care Holdings AG, Epredia Holdings Ltd., Wemex Corporation, and LSI Medience Corporation. With the mission to contribute to the health of society through healthcare solutions that have a positive impact and improve the lives of people, we are proud to offer our products and services to customers in more than 125 countries around the world.
www.phchd.com/global/phc
About Cyfuse Biomedical K.K.
Cyfuse Biomedical K.K. (TSE 4892) develops and sales, the Regenova® and S-PIKE® bio-3D printers, which comes with proprietary platform technology of bio-3D printing that creates 3D tissues made only from cells and without the aid of artificial scaffolding materials. This technology also develops innovative regenerative medicine products.
For more information on our business, platform technology, 3D cell product development, and bio-3D printers, visit our CYCHANNEL: www.cyfusebio.com/cychannel.
This alliance will have a small impact to our performance, but is an investment in building our corporate value. If any event that needs to be disclosed arises, we will disclose such information accordingly.
For enquiries:
Public Relations Section, Business Planning Department, In Vitro Diagnostics Division
PHC Corporation
Phone: +81-70-1449-9486
E-mail: ivd-communications@gg.phchd.com
[For IR and media enquiries]
Investor Relations & Corporate Communications Department
PHC Holdings Corporation
Phone: +81-3-6778-5311
E-mail: phc-pr@gg.phchd.com
Business Administration Department
Cyfuse Biomedical K.K.
Email: ir@cyfusebm.com